Yahoo
NasdaqGS - Delayed Quote USD

Bio-Techne Corporation (TECH)

72.73 +0.07 (+0.10%)
At close: November 4 at 4:00:01 PM EST
72.73 -0.01 (-0.01%)
After hours: November 4 at 4:00:38 PM EST
Trade TECH on Coinbase

Key Executives

Amounts are as of December 31, 2026 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. James T. Hippel CPA
Executive VP of Finance & CFO 1.38M 3.63M 1971
Mr. Shane V. Bohnen
Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer 884.35k 76.27k 1975
Mr. William A. Geist
President of Protein Sciences Segment 1.06M -- 1969
Mr. Steven C. Crouse
President of Diagnostics & Spatial Biology Segment 667.96k -- 1973
Dr. Gary J. Latham Ph.D.
VP & CTO -- -- --
Mr. David Clair C.F.A.
Vice President of Investor Relations -- -- --
Mr. Martin Wirtz
Senior Vice President of Strategy & Corporate Development -- -- --
Ms. Cheryl Bethune
Senior VP & Chief Human Resources Officer -- -- --
Mr. Luca Cicchetti
Managing Director -- -- --
Dr. Bernie Andruss
Senior Vice President of Bio-Techne Diagnostics Division -- -- --

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854 https://www.bio-techne.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
3,000

Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Bio-Techne Corporation’s ISS Governance QualityScore as of November 1, 2026 is 8. The pillar scores are Audit: 7; Board: 1; Shareholder Rights: 1; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 9, 2026 at 1:30 PM UTC

Bio-Techne Corporation Earnings Date

Recent Events

November 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 28, 2026 at 12:00 AM UTC

10-K/A: Periodic Financial Reports

September 23, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 14, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 9, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

September 4, 2026 at 12:00 AM UTC

Dividend Date

September 2, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

August 25, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

August 24, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

August 24, 2026 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: